Navigation Links
Caraco Pharmaceutical Laboratories, Ltd. Announces Reversal of Summary Judgment in Ultracet(R) ANDA Patent Litigation
Date:8/27/2009

DETROIT, Aug. 27 /PRNewswire-FirstCall/ -- Caraco Pharmaceutical Laboratories, Ltd. (NYSE Amex: CPD) announced today that a US Federal Circuit Court has reversed a portion of a previously decided summary judgment on ANDA Patent litigation between Ortho McNeil and Caraco regarding Ultracet(R). The court has remanded the litigation to a lower court for further proceedings. The court did find that a portion of the patent was not valid. Caraco believes in the merits of its case and is evaluating its further options.

Detroit-based Caraco Pharmaceutical Laboratories, Ltd., develops, manufactures, markets and distributes generic and private-label pharmaceuticals to the nation's largest wholesalers, distributors, drugstore chains and managed care providers.

Safe Harbor: This news release contains forward-looking statements made pursuant to the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. Without limitation, the words "believe" or "expect" and similar expressions are intended to identify forward-looking statements. Such statements are based on management's current expectations and are subject to risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties are contained in the Corporation's filings with the Securities and Exchange Commission, including Part I, Item 1A of our most recent Form 10-K, and include but are not limited to: information of a preliminary nature that may be subject to adjustment, potentially not obtaining or delay in obtaining FDA approval for new products, governmental restrictions on the sale of certain products, development by competitors of new or superior products or less expensive products or new technology for the production of products, the entry into the market of new competitors, market and customer acceptance and demand for new pharmaceutical products, availability of raw materials, timing and success of product development and launches, dependence on few products generating majority of sales, product liability claims for which the Company may be inadequately insured, and other risks identified in this report and from time to time in our periodic reports and registration statements. These forward-looking statements represent our judgment as of the date of this report. We disclaim, however, any intent or obligation to update our forward-looking statements.


'/>"/>
SOURCE Caraco Pharmaceutical Laboratories, Ltd.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Caraco Pharmaceutical Laboratories, Ltd. Markets Generic Imitrex(R) Tablets
2. Caraco Pharmaceutical Laboratories, Ltd. Announces Settlement of Ethyol(R) ANDA Patent Litigation
3. Caraco Pharmaceutical Laboratories, Ltd. Announces Change to Executive Team as Jitendra N. Doshi Assumes Position of CEO
4. Caraco Pharmaceutical Laboratories, Ltd. Reports Results for the First Quarter of Fiscal Year 2010
5. Caraco Pharmaceutical Laboratories, Ltd. Announces Filing of Purported Class Action Lawsuits
6. Forest Laboratories and H. Lundbeck A/S Enter Into Settlement Agreement With Sun and Caraco Related to LEXAPRO(R) Patent Litigation
7. Caraco Pharmaceutical Laboratories, Ltd. Enters Into Asset Purchase Agreement with Forest Laboratories, Inc. to Settle Lexapro(R) (escitalopram oxalate) ANDA Patent Litigation
8. Caraco Pharmaceutical Laboratories, Ltd. Announces an Indefinite Reduction in its Workforce
9. Caraco Pharmaceutical Laboratories, Ltd. Updates on Financial Position
10. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Action
11. Caraco Pharmaceutical Laboratories, Ltd. Reports Results for the Fiscal Year 2009, Updates on FDA Inspection
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2017)... ... August 21, 2017 , ... Marathon ... all over the country. , Outdoor running increases exposure to ultraviolet radiation, a ... increased risk of melanoma, and only half may be adequately protecting themselves with ...
(Date:8/21/2017)... (PRWEB) , ... August 21, 2017 , ... San Diego ... ) health care reform plan, has announced his candidacy for the 52nd Congressional District ... and shared in America’s Promise. Coming to this country at age eleven after suffering ...
(Date:8/20/2017)... ... ... State Farm Neighborhood Assist® has named The Southern Maryland Team Anti-Bullying Program ... initiative wins, Gals Lead – Dream Queen Foundation’s signature teen girl program to help ... Calvert and Charles Counties. The program could potentially impact nearly 17,500 female students (49.4 ...
(Date:8/19/2017)... MD (PRWEB) , ... August 18, 2017 , ... ... and Drug Administration Reauthorization Act of 2017, legislation that provides for greater public ... mild to moderate hearing loss to access OTC hearing aids without being seen ...
(Date:8/19/2017)... ... August 19, 2017 , ... Parker at Stonegate, an assisted ... passionate employees, caregivers, volunteers, thought leaders, researchers, educators and partners leading the way ... time to refresh the carpeting with the goal of maintaining the same precise ...
Breaking Medicine News(10 mins):
(Date:8/15/2017)... 15, 2017 Diplomat Pharmacy, Inc. (NYSE: DPLO), ... Michigan residents. Naloxone is available ... retail pharmacy, G-3320 Beecher Road. ... and Drug Administration, is intended to block or reverse ... and loss of consciousness. The medication is often carried ...
(Date:8/14/2017)... N.J. and PETACH TIKVAH, Israel ... Inc. (NASDAQ: BCLI), a leading developer of adult stem ... the second quarter ending June 30, 2017. ... stages of preparing for our pivotal Phase 3 trial ... Chaim Lebovits , President and Chief Executive Officer of ...
(Date:8/8/2017)... DUBLIN, Aug. 8, 2017   ... $3.12 diluted (GAAP) loss per share from continuing operations ... Products revenues increased 16 percent to $110 million ... increased 27 percent to $161 million ... (EPS) from continuing operations increased 8 percent to $0.93 ...
Breaking Medicine Technology: